Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

U.S. should have enough COVID-19 vaccine by Q3 2021, CDC head tells Senate panel

By Nancy Crotti | September 16, 2020

CDC director Dr. Robert Redfield told a Senate panel today that the federal government should have enough coronavirus vaccine for Americans to resume “regular life” by the third quarter of 2021, according to a report by CNBC.

Redfield said vaccinations could begin November or December of 2020 and that it could take 6 to 9 months to inoculate all Americans, the network reported.

“If you’re asking me when is it going to be generally available to the American public so we can begin to take advantage of vaccine to get back to our regular life, I think we’re probably looking at third … late second quarter, third quarter 2021,” Redfield told the U.S. Senate Appropriations Subcommittee on Labor, Health and Human Services, Education, and Related Agencies.

The Trump administration today released a plan to distribute an eventual COVID-19 vaccine free of charge, initially to targeted groups and more broadly as supply increases. The government is planning a phased distribution using a contract awarded to McKesson in August. The first recipients could include:

  • Healthcare personnel likely to be exposed to or treat people with COVID-19.
  • People at increased risk for severe illness from COVID-19, including those with underlying medical conditions and people 65 years of age and older.
  • Other essential workers.

Final decisions will depend in part on the proven efficacy of the vaccines coming out of Phase 3 trials, according to an interim vaccine distribution “playbook” released today along with a distribution strategy document.


Filed Under: Drug Delivery
Tagged With: coronavirus, covid-19, U.S. Centers for Disease Control and Prevention (CDC), U.S. Senate
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Theravision_FDA Revised Carton
Johnson & Johnson is bringing the world’s first drug-eluting contact lens to market
midatech pharma janssen johnson & Johnson
J&J expands it long-acting injectables partnership with Midatech
Evonik launches new Eudratec tech to boost solubility of oral small molecules
PharmaJet Stratis
PharmaJet partner touts interim safety results for needle-free COVID-19 vaccine

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50